- Home
- DARE vs RDI Comparison
DARE vs RDI Comparison
Compare DARE & RDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DARE
- RDI
- Stock Information
- Founded
- DARE 2015
- RDI 1937
- Country
- DARE United States
- RDI United States
- Employees
- DARE N/A
- RDI N/A
- Industry
- DARE Biotechnology: Pharmaceutical Preparations
- RDI Movies/Entertainment
- Sector
- DARE Health Care
- RDI Consumer Discretionary
- Exchange
- DARE Nasdaq
- RDI Nasdaq
- Market Cap
- DARE 26.3M
- RDI 30.6M
- IPO Year
- DARE N/A
- RDI N/A
- Fundamental
- Price
- DARE $2.52
- RDI $1.33
- Analyst Decision
- DARE Strong Buy
- RDI Hold
- Analyst Count
- DARE 3
- RDI 1
- Target Price
- DARE $12.50
- RDI $2.40
- AVG Volume (30 Days)
- DARE 443.5K
- RDI 32.9K
- Earning Date
- DARE 08-11-2025
- RDI 08-13-2025
- Dividend Yield
- DARE N/A
- RDI N/A
- EPS Growth
- DARE N/A
- RDI N/A
- EPS
- DARE N/A
- RDI N/A
- Revenue
- DARE $25,909.00
- RDI $205,644,000.00
- Revenue This Year
- DARE $99,756.91
- RDI $7.47
- Revenue Next Year
- DARE $119.77
- RDI $13.22
- P/E Ratio
- DARE N/A
- RDI N/A
- Revenue Growth
- DARE N/A
- RDI N/A
- 52 Week Low
- DARE $2.11
- RDI $1.17
- 52 Week High
- DARE $4.60
- RDI $1.89
- Technical
- Relative Strength Index (RSI)
- DARE 41.75
- RDI 50.93
- Support Level
- DARE $2.37
- RDI $1.24
- Resistance Level
- DARE $2.54
- RDI $1.31
- Average True Range (ATR)
- DARE 0.14
- RDI 0.06
- MACD
- DARE -0.00
- RDI -0.00
- Stochastic Oscillator
- DARE 59.56
- RDI 62.50
About DARE Dare Bioscience Inc.
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.
About RDI Reading International Inc
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.